• Drug: Livtencity (maribavir)
  • Manufacturer: Takeda

  • Route of Administration: Oral

  • Site of Care: Outpatient
  • Approved Indication: treatment of adults and pediatric patients (12 years of age and older and weighing at least 35 kg) with post-transplant CMV infection/disease that is refractory to treatment (+/- genotypic resistance) with ganciclovir, valganciclovir, cidofovir, or foscarnet
  • Disease: post-transplant cytomegalovirus (CMV) infection

  • Therapeutic Area: Infectious disease

  • Enrollment Form Link: livtencity.com/access
  • Phone Number: 1-855-268-1825
  • Fax Number: 1-855-268-1826
  • Product Website: livtencity.com